Themis Medicare gains on getting DCGI nod for antiviral drug ‘Viralex’
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Themis Medicare is currently trading at Rs. 1027.00, up by 9.65 points or 0.95% from its previous closing of Rs. 1017.35 on the BSE.
The scrip opened at Rs. 1053.00 and has touched a high and low of Rs. 1055.00 and Rs. 1027.00 respectively. So far 308 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 1198.80 on 16-Aug-2021 and a 52 week low of Rs. 271.70 on 31-Mar-2021.
Last one week high and low of the scrip stood at Rs. 1055.00 and Rs. 968.10 respectively. The current market cap of the company is Rs. 944.87 crore.
The promoters holding in the company stood at 67.18%, while Institutions and Non-Institutions held 0.01% and 32.81% respectively.
Themis Medicare has received approval for its antiviral drug ‘Viralex’ from the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate COV1D- 19 patients.
In line with the DCGI's current approach for approval of medicines for the management of the ongoing pandemic, approval for Viralex (Generic name: lnosine pranobex) is based on the results of the robust phase 2 and phase 3 RCTs conducted in India, and the well-established safety profile of the drug.
As per the results of the Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with Viralex showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group (52.38%) among the mild to moderate non-hospitalized COVID-19 patients. Clinical Cure (complete relief from symptoms) was also seen in significantly higher number of patients in the Viralex group as compared to that in the placebo group on day 6 of treatment. There was early improvement and complete relief from symptoms in patients who received Viralex. This drug was well tolerated by the patients without any serious side effects. The study was conducted during the Delta wave of the pandemic.
Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.
 23.jpg)
